신생아 호흡곤란증후군에서 인공 폐표면활성제의 사용 = The use of artificial pulmonary surfactant in neonatal respiratory distress

다국어 초록 (Multilingual Abstract)

Pulmonary surfactant instillation is the treatment of choice in neonatal respiratory distress syndrome. The development of artificial surfactant has three decades of history. Animal-derived artificial surfactant is used in most countries and consists of 80% phospholipids and glycerol. 10% of the formulation is comprised of surfactant proteins, which have the critical role in surfactant function of lowering surface tension in the alveoli. Synthetic surfactants are made using synthetic peptide analogues as the surfactant protein counterparts. These are not the same as the human surfactant protein sequences; however, researchers are attempting to find the ideal synthetic peptide sequence for use in synthetic surfactants. Prophylactic and rescue surfactant therapy are two main therapeutic options. A recent recommendation emphasizes the importance of rescue therapy with continuous positive nasal airway pressure, rather than prophylactic use immediate after birth. This article briefly reviews the history and physiology of surfactant use, as well as clinical practice of surfactant and future studies.

참고문헌 (Reference)

1 김영돈, "신생아 호흡곤란증 치료를 위한 새로운 합성 표면활성제" 대한신생아학회 19 (19): 184-194, 2012

2 Kirsten GF, "The outcome of ELBW infants treated with NCPAP and InSurE in a resource-limited institu-tion" 129 : 952-959, 2012

3 Robertson B, "Synthetic surfactants to treat neonatal lung disease" 6 : 119-124, 2000

4 Moya F., "Synthetic surfactants : where are we? Evidence from randomized, controlled clinical trials" 29 (29): 23-28, 2009

5 Almlen A, "Synthetic surfactant based on analogues of SP-B and SP-C is superior to single-peptide surfactants in ventilated premature rabbits" 98 : 91-99, 2010

6 Almlen A, "Surfactant proteins B and C are both necessary for alveolar stability at end expiration in premature rabbits with respiratory distress syndrome" 104 : 1101-1108, 2008

7 Clements JA, "Surface tension of lung extracts" 95 : 170-172, 1957

8 Avery ME, "Surface properties in relation to atelec-tasis and hyaline membrane disease" 97 : 517-523, 1959

9 Soll RF, "Prophylactic versus selective use of surfac-tant in preventing morbidity and mortality in preterm infants" (2) : CD000510-, 2001

10 Rojas-Reyes MX, "Prophylactic versus se-lective use of surfactant in preventing morbidity and mor-tality in preterm infants" 3 : CD000510-, 2012

11 Kang JH, "Preparation and in vitro physical activities of crude natural surfactant and artificial pulmonary surfactant containing synthetic peptide and phospholipid mixtures" 41 : 472-480, 1998

12 Seehase M, "New surfactant with SP-B and C analogs gives survival benefit after inactivation in preterm lambs" 7 : e47631-, 2012

13 More K, "Minimally invasive surfactant administration in preterm infants : a meta-narrative review" 168 : 901-908, 2014

14 Robillard E, "Microaerosol administration of synthetic beta-gamma-dipalmitoyl-l-alpha-lecithin in the respiratory distress syn-dome : a preliminary report" 90 : 55-57, 1964

15 Metcalfe IL, "Lung expansion and survival in rabbit neonates treated with surfac-tant extract" 53 : 838-843, 1982

16 Moya FR, "International Surfaxin Colla-borative Study Group. A multicenter, randomized, masked, comparison trial of lucinactant, colfosceril palmitate, and beractant for the prevention of respiratory distress syndrome among very preterm infants" 115 : 1018-1029, 2005

17 Pillow JJ, "Innovation in surfactant therapy II : surfactant administration by aerosolization" 101 : 337-344, 2012

18 Gopel W, "German Neonatal Network. Avoidance of mechanical ventil-ation by surfactant treatment of spontaneously breathing pre-term infants (AMV) : an open-label, randomised, controlled trial" 378 : 1627-1634, 2011

19 Sweet DG, "European Association of Perinatal Medicine. European consensus guidelines on the management of neonatal res-piratory distress syndrome in preterm infants : 2013 update" 103 : 353-368, 2013

20 Spragg RG, "Effect of recombinant surfactant protein C-based surfactant on the acute respiratory distress syndrome" 351 : 884-892, 2004

21 김성미, "Early Prophylactic versus Late Selective Use of Surfactant for Respiratory Distress Syndrome in Very Preterm Infants: A Collaborative Study of 53 Multi-Center Trials in Korea" 대한의학회 29 (29): 1126-1131, 2014

22 SUPPORT Study Group of the Eunice Kennedy Shriver NICHD Neonatal Research Network, "Early CPAP ver-sus surfactant in extremely preterm infants" 362 : 1970-1979, 2010

23 Fujiwara T, "Artificial surfactant therapy in hyaline-membrane disease" 1 : 55-59, 1980

24 Lewis JF, "Aerosolized surfac-tant treatment of preterm lambs" 70 : 869-876, 1991

25 Robertson B, "A 2-year follow up of babies enrolled in a European multicentre trial of porcine surfactant replacement for severe neonatal respiratory distress syndrome. Collaborative European Multi-centre Study Group" 151 : 372-376, 1992